INDP:NASDAQIndaptus Therapeutics, Inc. analysis
Data as of Oct 6, 2026 - not real-time
- Latest price
- $2.51
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind Indaptus Therapeutics, Inc. is neutral at $2.51, with no clear ordering between short and long averages. It has gained 94.6% over the past 30 days. Relative strength is 48.5 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $1.27 and resistance around $4.22.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 219.4%, a beta of 1.87 and a maximum drawdown of 80.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 5 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 219.4%, a beta of 1.87 and a maximum drawdown of 80.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is sell, conviction 5 out of 10.
Top market events
- Nasdaq1monIndaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateNEW YORK,...
- Kalkine Media5dIndaptus Therapeutics Pushes Private Placement Closing Date to October 16, 2026INDP NASDAQ:INDP...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Trading above the 200-day average of 2.27
- MACD momentum is negative
- 30-day price change of +94.6%
Medium term
1–3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Trading above the 200-day average of 2.27
- 30-day volatility of 219.4%
- MACD momentum is negative
Long term
> 3 yearsCautious
Model confidence5/105 out of 10
Key factors
- Negative return on equity of -318.0%
- Negative free cash flow
- 30-day volatility of 219.4%
Key metrics
Financial health
P/E Ratio-1.8
ROE-318.04%
ROA-98.08%
P/B Ratio29.5
Op. Cash Flow$-14695567
Free Cash Flow$-9672618
Industry P/E29.9
Technical analysis
TrendNeutral
RSI48.5
Support$1.27
Resistance$4.22
MA 20$3.04
MA 50$1.96
MA 200$2.27
MACDBearish
VolumeDecreasing
Fear & Greed Index93.71
Valuation
GradeOvervalued
TypeGrowth
Risk assessment
Beta1.87
Volatility219.42%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.